Posted March 17, 2014 by lorrainegenscript
A recent publication in Science Translational Medicine describes the use of a humanized monoclonal antibody against activated FXIIa, identified using phage display, to prevent the formation of blood clots without increasing the risk of bleeding.
Contact Email | [email protected] |
Issued By | lorraine xu |
Website | A recent publication in Science Translational Medicine describes the use of a humanized monoclonal antibody against activated FXIIa, identified using phage display, to prevent the formation of blood clots without increasing the risk of bleeding. Prevent |
Country | China |
Categories | Health |
Tags | antibody , genscript |
Last Updated | March 17, 2014 |